Free Trial
NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

Orgenesis logo
$0.10 -0.90 (-90.00%)
As of 09:30 AM Eastern

About Orgenesis Stock (NASDAQ:ORGS)

Key Stats

Today's Range
$0.10
$0.10
50-Day Range
$0.00
$1.84
52-Week Range
$0.00
$7.61
Volume
280 shs
Average Volume
7,198 shs
Market Capitalization
$479.90 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orgenesis Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
26th Percentile Overall Score

ORGS MarketRank™: 

Orgenesis scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Orgenesis.

  • Percentage of Shares Shorted

    0.37% of the float of Orgenesis has been sold short.
  • Short Interest Ratio / Days to Cover

    Orgenesis has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Orgenesis has recently increased by 104.94%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Orgenesis does not currently pay a dividend.

  • Dividend Growth

    Orgenesis does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.37% of the float of Orgenesis has been sold short.
  • Short Interest Ratio / Days to Cover

    Orgenesis has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Orgenesis has recently increased by 104.94%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Orgenesis has a news sentiment score of -0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Orgenesis this week, compared to 0 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Orgenesis insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.66% of the stock of Orgenesis is held by insiders.

  • Percentage Held by Institutions

    Only 22.56% of the stock of Orgenesis is held by institutions.

  • Read more about Orgenesis' insider trading history.
Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

ORGS Stock News Headlines

Orgenesis Director Ashish Nanda Resigns
BREAKING: The House just passed 3 pro-crypto bills!
THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. tc pixel
Orgenesis Delays Filing of Quarterly Report
Orgenesis secures $5M equity investment from Williamsburg Venture
See More Headlines

ORGS Stock Analysis - Frequently Asked Questions

Orgenesis' stock was trading at $1.89 on January 1st, 2025. Since then, ORGS shares have decreased by 94.7% and is now trading at $0.10.

Orgenesis Inc. (NASDAQ:ORGS) issued its earnings results on Friday, August, 11th. The company reported ($1.50) earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by $2.10. The company earned $6.98 million during the quarter.

Orgenesis shares reverse split on Wednesday, September 25th 2024.The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

The following companies are subsidiaries of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB).

Company Calendar

Last Earnings
8/11/2023
Today
8/25/2025
Next Earnings (Estimated)
11/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORGS
CIK
1460602
Fax
N/A
Employees
150
Year Founded
2008

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$55.36 million
Net Margins
-3,827.81%
Pretax Margin
-3,931.93%
Return on Equity
N/A
Return on Assets
-130.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.07
Quick Ratio
0.07

Sales & Book Value

Annual Sales
$662 thousand
Price / Sales
0.72
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($6.58) per share
Price / Book
-0.02

Miscellaneous

Outstanding Shares
4,799,000
Free Float
4,527,000
Market Cap
$479.90 thousand
Optionable
No Data
Beta
0.44

Social Links

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:ORGS) was last updated on 8/25/2025 by MarketBeat.com Staff
From Our Partners